Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score

Natalie Logie, Rachel B. Jimenez, Natalie Pulenzas, Kelly Linden, Denise Ciafone, Sunita Ghosh, Yuhui Xu, Shilo Lefresne, Erin Wong, Christina H. Son, Helen A. Shih, William W. Wong, Scott Tyldesley, Kristopher Dennis, Edward Chow, Alysa M. Fairchild

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose Whole brain radiation therapy (WBRT) remains the standard of care for patients with multiple brain metastases, but more than half of treated patients will develop intracranial progression. Because there is no clear consensus on the optimal therapeutic approach, a prognostic index would be helpful to guide treatment options at progression. We explored whether the recursive partitioning analysis (RPA) score prior to repeat WBRT is predictive of survival. Methods and materials This multi-institutional pooled analysis included patients with 2 or more brain metastases from any solid primary tumor that was treated with 2 courses of WBRT. Information on demographics, disease characteristics, and intervals between courses was collected. RPA class was abstracted or retrospectively assigned, and descriptive statistics calculated. Median survival (MS) was determined using the Kaplan-Meier method and compared using log rank tests. Univariate and multivariate analyses were performed via Cox regression analysis. Results For 205 patients, the median age was 55 years (range, 25-83 years), 68% were female, 40.5% had non-small cell lung cancer, and 31.2% had small cell lung cancer. Prior to the second WBRT, 4.9% of patients were RPA class 1, 36.6% were RPA2, and 58.5% were RPA3, with an MS of 7.5 months (95% confidence interval [CI], 4.7-10.3), 5.2 months (95% CI, 3.7-6.7 months), and 2.9 months (95% CI, 2.2-2.9 months), respectively (P = .001). On univariate and multivariate analyses, a Karnofsky Performance Status of <80, extracranial metastases, interval between courses <9 months, small cell lung cancer histology, and uncontrolled primary significantly correlated with shorter MS. By assigning a score of 1 to each of these factors, a new prognostic index was created, the reirradiation (ReRT) score. Survival on the basis of ReRT score grouping ranged from 2.2 to 7.2 months and demonstrated significant differences in MS. Conclusions In the largest reported cohort to receive repeat WBRT, application of the RPA score was not predictive of MS. The new ReRT score is a simple tool based on readily available clinical information.

Original languageEnglish (US)
Pages (from-to)381-390
Number of pages10
JournalAdvances in Radiation Oncology
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score'. Together they form a unique fingerprint.

  • Cite this

    Logie, N., Jimenez, R. B., Pulenzas, N., Linden, K., Ciafone, D., Ghosh, S., Xu, Y., Lefresne, S., Wong, E., Son, C. H., Shih, H. A., Wong, W. W., Tyldesley, S., Dennis, K., Chow, E., & Fairchild, A. M. (2017). Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score. Advances in Radiation Oncology, 2(3), 381-390. https://doi.org/10.1016/j.adro.2017.05.010